Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944808 | 0.92 | KMT2A (0.46) | ALDH1A1MAPTKMT2AMEN1GAA | |
| SCHEMBL9944989 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPTKMT2ALMNAGAA | |
| SCHEMBL9944969 | 0.84 | ALDH1A1 (0.37) | ALDH1A1MAPTKMT2ALMNAGAA | |
| SCHEMBL9944769 | 0.84 | MAPT (0.48) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL9945032 | 0.84 | MAPT (0.48) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL9944846 | 0.83 | KMT2A (0.47) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL9944820 | 0.83 | ALDH1A1 (0.39) | ALDH1A1MAPTKMT2AGAAMAPK1 | |
| SCHEMBL9944991 | 0.83 | KDM4E (0.36) | ALDH1A1LMNAGAASMN1; SMN2POLB | |
| SCHEMBL9898442 | 0.81 | PTGES (0.45) | ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL9944753 | 0.80 | ALDH1A1 (0.39) | ALDH1A1MAPTKMT2AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | ALDH1A1 126/4885MAPT 4336/4885KMT2A 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.